Menu

US Government to Repatriate Kennewick Man

A 2015 ancient DNA study determined that the 8,500-year-old skeletal remains belonged to an individual of Native American ancestry. Now, the US Army Corp of Engineers has begun the process of returning the bones to their rightful owners.

Apr 29, 2016
Bob Grant

IMAGE: CHIP CLARK/SMITHSONIAN INSTITUTIONLast year, an international team used ancient DNA technology to determine that the 8,500-year-old “Kennewick Man” skeleton was Native American. Researchers at the University of Chicago independently verified the finding earlier this month. And now, the US government has made it official: the Army Corp of Engineers, after reviewing the data on Kennewick Man, has declared that the remains—which it currently owns—are in fact of Native American origin. “I find that there is substantial evidence to determine that Kennewick Man is related to modern Native Americans from the United States,” Army Brigadier General Scott Spellmon, commander of the Army Corps’ Northwestern Division, said in a report released this week (April 26).

The official statement paves the way for Native American tribes to reclaim and bury the remains, which scientists discovered on Army Corp land along the Columbia River in Washington in 1996. Since their unearthing, the remains have served as the focal point for a litany of legal filings—suits filed against the Army Corp by researchers seeking to study the bones and similar legal claims made by Native American tribes trying to obtain Kennewick Man. And previous anthropolocial research suggested that Kennewick Man may have been of Asian or Caucasian extraction. “Obviously we are hearing an acknowledgment from the Corps of what we have been saying for 20 years,” JoDe Goudy, chairman of the Yakama Nation, told The Seattle Times. “Now we want to collectively do what is right, and bring our relative back for reburial.”

But because the Army Corp has acknowledged the Native American provenance of the Kennewick Man skeleton, it means that the remains now fall under the jurisdiction of the Native American Graves Protection and Repatriation Act, a framework for returning such items to their rightful owners, Native American tribes. The trouble with Kennewick Man, however, is that no one is sure exactly which tribe he belonged to. Several Northwestern tribes—including the Colville, Yakama, Umatilla, Nez Perce, and Wanapum—have staked claims to the bones in the past. “We’re looking through our options and discussing it with the other tribes involved to determine how best to get repatriation done,” Chuck Sams, a spokesperson for the Confederated Tribes of the Umatilla Indian Reservation, told The Christian Science Monitor.

Michael Coffey, a spokesperson for the Army Corps in Portland, Oregon, told The Washington Post that determining which tribe would get Kennewick Man could be a lengthy process. “We still have a lot of work to do,” she said.

Coffey added that February 2017 would be the earliest time at which specific cultural ties to the remains would be confirmed to the level that that is required for repatriation.

For now, Kennewick Man will remain at the Burke Museum in Seattle and under the Army Corps’ ownership. “At present, there has been no decision to transfer the remains,” Spellmon said in the statement.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.